The transaction is subject to regulatory and other approvals and is expected to close in the next couple of months.
Given expectation of rise in prices, TSL and JSTL upgraded to ‘Buy’ and SAIL to ‘Neutral’.
Q3 is expected to be strong; ‘Buy’ maintained; top pick in the mid-cap space
In the current environment, using the proceeds to support the core via lower leverage / higher liquidity would be prudent,…
We maintain estimates despite another quarter of margin and PAT beat, as GP margins could begin to compress with a…
16/21% revenue/earnings CAGR estimated over FY18-21e; initiated with ‘Buy’ and TP of Rs 425; valuations are attractive.
Fall in e-auction volumes and lower FSA realisations behind earnings miss; ‘Buy’ retained on account of a host of positives
At Rs 6.5 billion (Citi Rs 6.9 billion), Q1 adjusted Ebitda fell 10% year-on-year — volume growth and higher power…
1QFY19 PAT at Rs 46.0 billion (+18% year-on-year, -4% quarter-on-quarter) was 3% below our estimates and 4% below consensus. Margin…
Next 6-12 months critical as company could launch multiple biosimilars in US and EU; TP at `720; remains one of…
Robust earnings growth likely over next few years; ‘Buy’ rating with TP at Rs 350.
EPS CAGR of 22% expected over FY17-20e and an ROE of 50%; TP at Rs 327.
Edelweiss Financial Services (EDEL) reported earnings of Rs 2.36 bn (+52% y-o-y, +13% q-o-q) were ~10% ahead of our estimates,…
We believe the nascent recovery seen in the last few months has more legs — with our earlier concerns of…
Company has made progress in most of its businesses over last year; however, valuations reflect this; TP up to Rs…
Cost of production that affected quarter expected to ease; there is strong dividend security; however, valuations are at peak
At Rs 72.8 bn, Q4 Ebitda more than doubled y-o-y — higher zinc/silver, ore, ally volumes; better prices, decline in discount to Brent in oil and gas;…
With stock outperforming the market by 33%, current valuation looks expensive.
